Start up. Grow up. Succeed.

Nexigen GmbH closes 5.6 Million Euro financing

Nexigen GmbH closed a further financing round totaling 5.6 million Euro with the participation of existing investors AT Newtec GmbH, FCPB Nex GmbH and MIG Fonds.

November 2014

The capital of this round shall be used for the further development of Nexigen's lead project in oncology. Nexigen's lead peptide targetin an intracellular component of the cancer stem cell-relevant Wnt signalling pathway recently demonstrated dual activity on tumor growth and tumor cell self-renewal (a cancer stem cell phenotype). The achievement of this in vivo proof-of-principlae validates Nexigen's proprietary screening platform to identify peptides interfering with disease-relevant protein-protein interactions.